These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 28005498)
21. Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus. Runge VM Invest Radiol; 2016 May; 51(5):273-9. PubMed ID: 26945278 [TBL] [Abstract][Full Text] [Related]
22. Anatomic distribution of gadolinium contrast medium by high-resolution magnetic resonance imaging after peribulbar and retrobulbar injections. Almeida DR; Belliveau MJ; Enright T; Islam O; El-Defrawy SR; Gale J Arch Ophthalmol; 2012 Jun; 130(6):743-8. PubMed ID: 22801836 [TBL] [Abstract][Full Text] [Related]
23. Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society" survey. Nachtigall LB; Karavitaki N; Kiseljak-Vassiliades K; Ghalib L; Fukuoka H; Syro LV; Kelly D; Fleseriu M Pituitary; 2019 Feb; 22(1):37-45. PubMed ID: 30456434 [TBL] [Abstract][Full Text] [Related]
24. Use of gadolinium-based magnetic resonance imaging contrast agents and awareness of brain gadolinium deposition among pediatric providers in North America. Mithal LB; Patel PS; Mithal D; Palac HL; Rozenfeld MN Pediatr Radiol; 2017 May; 47(6):657-664. PubMed ID: 28283727 [TBL] [Abstract][Full Text] [Related]
27. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status. Stojanov D; Aracki-Trenkic A; Benedeto-Stojanov D Neuroradiology; 2016 May; 58(5):433-41. PubMed ID: 26873830 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and tissue retention of (Gd-DTPA)-cystamine copolymers, a biodegradable macromolecular magnetic resonance imaging contrast agent. Wang X; Feng Y; Ke T; Schabel M; Lu ZR Pharm Res; 2005 Apr; 22(4):596-602. PubMed ID: 15846467 [TBL] [Abstract][Full Text] [Related]
29. Gadolinium in human brain sections and colocalization with other elements. El-Khatib AH; Radbruch H; Trog S; Neumann B; Paul F; Koch A; Linscheid MW; Jakubowski N; Schellenberger E Neurol Neuroimmunol Neuroinflamm; 2019 Jan; 6(1):e515. PubMed ID: 30568993 [No Abstract] [Full Text] [Related]
30. Exceeding the limits of the normal blood-brain barrier: quo vadis gadolinium? Levy LM AJNR Am J Neuroradiol; 2007; 28(10):1835-6. PubMed ID: 17898191 [No Abstract] [Full Text] [Related]
31. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. High WA; Ayers RA; Chandler J; Zito G; Cowper SE J Am Acad Dermatol; 2007 Jan; 56(1):21-6. PubMed ID: 17097388 [TBL] [Abstract][Full Text] [Related]
32. Hepatocyte-directed MR contrast agents. Can we take advantage of bile acids? Anelli PL; Calabi L; de Haën C; Lattuada L; Lorusso V; Maiocchi A; Morosini P; Uggeri F Acta Radiol Suppl; 1997; 412():125-33. PubMed ID: 9240091 [TBL] [Abstract][Full Text] [Related]
33. NSF-active and NSF-inert species of gadolinium: mechanistic and clinical implications. Kuo PH AJR Am J Roentgenol; 2008 Dec; 191(6):1861-3. PubMed ID: 19020260 [No Abstract] [Full Text] [Related]
34. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis. Abraham JL; Edward M AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307 [No Abstract] [Full Text] [Related]
35. A phantom-based feasibility study for detection of gadolinium in bone in-vivo using X-ray fluorescence. Lord ML; McNeill FE; Gräfe JL; Noseworthy MD; Chettle DR Appl Radiat Isot; 2016 Jun; 112():103-9. PubMed ID: 27019028 [TBL] [Abstract][Full Text] [Related]
36. Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy. Xia D; Davis RL; Crawford JA; Abraham JL Acta Radiol; 2010 Dec; 51(10):1126-36. PubMed ID: 20868305 [TBL] [Abstract][Full Text] [Related]
38. Accumulation of MRI contrast agents in malignant fibrous histiocytoma for gadolinium neutron capture therapy. Fujimoto T; Ichikawa H; Akisue T; Fujita I; Kishimoto K; Hara H; Imabori M; Kawamitsu H; Sharma P; Brown SC; Moudgil BM; Fujii M; Yamamoto T; Kurosaka M; Fukumori Y Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S355-8. PubMed ID: 19386506 [TBL] [Abstract][Full Text] [Related]
39. Survey of gadolinium-based contrast agent utilization among the members of the Society for Pediatric Radiology: a Quality and Safety Committee report. Blumfield E; Moore MM; Drake MK; Goodman TR; Lewis KN; Meyer LT; Ngo TD; Sammet C; Stanescu AL; Swenson DW; Slovis TL; Iyer RS Pediatr Radiol; 2017 May; 47(6):665-673. PubMed ID: 28283728 [TBL] [Abstract][Full Text] [Related]
40. Nephrogenic systemic fibrosis: some considerations on the debate regarding its cause. Provenzale JM AJR Am J Roentgenol; 2008 Dec; 191(6):1867-9. PubMed ID: 19020262 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]